Macrophage reprogramming, not CD8 T cell dynamics, characterizes durable disease control following PD-1 blockade in smoldering myeloma

Trial: NivoRd, single-arm phase II (NCT02903381; Dana-Farber IRB 16-242). n = 8 patients with high-risk smoldering multiple myeloma treated with nivolumab + lenalidomide + dexamethasone. Patients are identified by opaque codes (Pt01, Pt03–Pt09).

Contents: per-cell imaging mass cytometry (IMC) AnnData (n=8 paired pre/post bone-marrow biopsies; 72,619 cells × 34 markers); IMC phenotype tables (canonical 7-class lineages, Leiden clusters, 8 cellular neighborhoods); per-sample IMC summaries (lineage proportions, PD-L1+ fractions, CD4/CD8 ratio); LIANA differential ligand-receptor interactions (macrophage ↔ CD4-T, macrophage ↔ plasma-cell, pretreatment); cytogenetic-vs-expression validation tables; the MSigDB Hallmark 2020 GMT used for GSEA; per-patient response classifiers (DOR, COT, FAST, DOR_ordinal); and a README + data dictionary.

License: CC BY 4.0. Citation: Perron N. et al., Macrophage reprogramming, not CD8 T cell dynamics, characterizes durable disease control following PD-1 blockade in smoldering myeloma. (Manuscript under review, 2026.)